The Side Effects of Drugs Annual was first published in 1977. It has been continually published since then as a yearly update to the voluminous encyclopedia, Meyler's Side Effects of Drugs. Each new Annual continues to provide clinicians and medical investigators with a reliable and critical yearly survey of new data and trends in the area of adverse drug reactions and interactions. An international team of specialists has contributed to the informative Annual by critically interpreting it and by pointing to whatever is misleading.

• Each new Annual continues to provide clinicians and medical investigators with a reliable and critical yearly survey of new data and trends in the area of adverse drug reactions and interactions
• An international team of specialists has contributed to the informative Annual by critically interpreting it and by pointing to whatever is misleading

Contributors
Special reviews
Cumulative indexes of special reviews, Annuals 11-32
1 Index of drugs
2 Index of adverse reactions
Table of Essays, Annuals 1-32
Mechanistic and clinical descriptions of adverse drug reactions
1 EIDOS
2 DoTS
How to use this book
The scope of the Side Effects of Drugs Annuals
Period covered
Selection of material
Classification of drugs
Names of drugs and chemicals
System of tagging references
Indexes
Abbreviations
Side Effects Of Drugs Essay
Three generations
Renewed concern
Profiling the risk
A fourth generation?
The defenders
The view today
Conclusions
Chapter 1: Central nervous system stimulants and drugs that suppress appetite
Amphetamines [SED-15, 180; SEDA-30, 1; SEDA-31, 1; SEDA-32, 1]
Methylxanthines
Drugs that suppress appetite [SEDA-30, 7; SEDA-31, 9; SEDA-32, 16]
Drugs used in Alzheimer's disease [SEDA-30, 8; SEDA-31, 10; SEDA-32, 19]
Chapter 2: Antidepressant drugs
General
Monoamine oxidase inhibitors [SED-15, 2371; SEDA-32, 32]
Selective serotonin re-uptake inhibitors (SSRIs) [SED-15, 3109; SEDA-30, 16; SEDA-31, 18; SEDA-32, 33]
Serotonin and noradrenaline re-uptake inhibitors (SNRIs)
Other antidepressants
Chapter 3: Lithium
Chapter 4: Drugs of abuse
Cannabinoids [SED-15, 614; SEDA-30, 31; SEDA-31, 33; SEDA-32, 55]
Cocaine [SED-15, 848; SEDA-30, 31; SEDA-31, 37; SEDA-32, 58]
Opioid analgesics
Chapter 5: Hypnosedatives and anxiolytics
Azaspirones [SEDA-28, 52; SEDA-32, 75]
Benzodiazepines [SED-15, 429; SEDA-30, 49; SEDA-31, 57; SEDA-32, 75]
Benzodiazepine-like drugs
Benzodiazepine antagonists
Other hypnosedatives
Chapter 6: Antipsychotic drugs
General [SED-15, 2438; SEDA-32, 83]
Individual drugs
Chapter 7: Antiepileptic drugs
General
Chapter 8: Opioid analgesics and narcotic antagonists
General
Opioid receptor agonists
Partial opioid receptor agonists
Opioid receptor antagonists
Chapter 9: Anti-inflammatory and antipyretic analgesics and drugs used in gout
Amidopyrine and related compounds
Aniline derivatives [SED-15, 2679; SEDA-30, 129]
Anthranilic acid derivatives
Arylalkanoic acid derivatives [SED-15, 2555; SEDA-31, 186; SEDA-32, 229]
COX-2 selective inhibitors [SEDA-30, 130; SEDA-31, 190; SEDA-32, 232]
Indoleacetic acids [SEDA-25, 134]
Oxicams [SEDA-15, 2555; SEDA-28, 128; SEDA-30, 132; SEDA-32, 233]
Pyrazolone derivatives (phenylbutazone and related compounds) [SEDA-27, 111]
Salicylates [SED-15, 15; SEDA-30, 128]
Miscellaneous drugs
Drugs used in the treatment of gout
Chapter 10: General anesthetics and therapeutic gases
Anesthetic vapors [SEDA-30, 137; SEDA-31, 217; SEDA-32, 243]
Other vapors
Intravenous agents: non-barbiturate anesthetics
Intravenous agents: barbiturate anesthetics
Chapter 11: Local anesthetics
General
Effects related to modes of use [SED-15, 2121; SEDA-30, 152; SEDA-31, 233; SEDA-32, 262]
Caudal, epidural, and spinal anesthesia
Individual compounds
Chapter 12: Neuromuscular blocking agents and skeletal muscle relaxants
Depolarizing neuromuscular blocking agents
Non-depolarizing neuromuscular blocking agents [SED-15, 2489; SEDA-31, 248; SEDA-32, 274]
Skeletal muscle relaxants
Chapter 13: Drugs that affect autonomic functions or the extrapyramidal system
Drugs that stimulate both alpha- and beta-adrenoceptors [SEDA-30, 170; SEDA-31, 259; SEDA-32, 281]
Drugs that predominantly stimulate alpha1-adrenoceptors [SEDA-27, 147; SEDA-30, 172; SEDA-31, 264; SEDA-32, 283]
Drugs that stimulate beta1-adrenoceptors [SEDA-30, 173; SEDA-31, 265; SEDA-32, 284]
Drugs that stimulate beta2-adrenoceptors
Other drugs that increase dopamine activity
Drugs that affect the cholinergic system [SEDA-30, 177; SEDA-31, 272; SEDA-32, 290]
Chapter 14: Dermatological drugs, topical agents, and cosmetics
Cosmetics
Dermal fillers
Dyestuffs [SEDA-15, 1573; SEDA-30, 182; SEDA-31, 288; SEDA-32, 296]
Fragrances
Phototherapy and photochemotherapy [SED-15, 2823; SEDA-32, 297]
Vitamin A (retinoids) [SED-15, 3653; SEDA-30, 185; SEDA-32, 298; for vitamin A carotenoids see Chapter 34]
Vitamin D analog